Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 4, Issue 9, 2009, Pages 1075-1082

  Qi, Yingwei ^a   Schild, Steven E ^b   Mandrekar, Sumithra J ^a   Tan, Angelina D ^a   Krook, James E ^c   Rowland, Kendrith M ^d   Garces, Yolanda I ^a   Soori, Gamini S ^e   Adjei, Alex A ^f   Sloan, Jeff A ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c Duluth Clinic   (United States)

^d Carle Cancer Center CCOP   (United States)

^e Missouri Valley Cancer Consoritum CCOP   (United States)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Non small cell; QOL; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CARBOXYAMINOIMIDAZOLE; CEMADOTIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EDATREXATE; GEFITINIB; GEMCITABINE; IMIDAZOLE DERIVATIVE; NAVELBINE; PACLITAXEL; PLACEBO; UNCLASSIFIED DRUG; VINBLASTINE;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FUNCTIONAL ASSESSMENT; GENDER; HUMAN; LABORATORY TEST; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; PSYCHOMETRY; QUALITY OF LIFE; RISK FACTOR; SCORING SYSTEM; SYMPTOM;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HEMOGLOBINS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE;

EID: 69549086346     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181ae27f5     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. NCI. Cancer Statistics Review 1975-2002.
3. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
4. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98. (Pubitemid 34438899)
5. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991;9:1618-1626.
6. Mandrekar SJ, Schild SE, Hillman SL, et al. A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Cancer 2006;107:781-792. (Pubitemid 44232670)
7. Sculier JP, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P; International Staging Committee and Participating Institutions. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol 2008;3:457-466. (Pubitemid 351630271)
8. Grothey A, Sargent DJ, Szydlo DW, Zhao X, Campbell M, Goldberg RM, Sloan JA. Baseline quality of life (QOL) is a strong and performance status (PS)-independent prognostic factor for overall survival (OS) in patients with metastatic colorectal cancer (mCRC). ASCO 2008 Gastrointestinal Cancers Symposium. Abstract No. 334.
9. Park SH, Cho MS, Kim YS, et al. Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy. Qual Life Res 2008;17:207-214.
10. Yeo W, Mo FK, Koh J, et al. Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann Oncol 2006;17:1083-1089. (Pubitemid 43985243)
11. Carey MS, Bacon M, Tu D, Butler L, Bezjak A, Stuart GC. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer. Gynecol Oncol 2008;108:100-105. (Pubitemid 350299429)
12. Langendijk H, Aaronson NK, de Jong JM, ten Velde GP, Muller MJ, Wouters M. The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy. Radiother Oncol 2000;55:19-25. (Pubitemid 30219430)
13. Efficace F, Bottomley A, Smit EF, et al; The EORTC Lung Cancer Group and Quality of Life Unit. Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol 2006;17:1698-1704. (Pubitemid 44680892)
14. Maione P, Perrone F, Gallo C, et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol 2005;23:6865-6872. (Pubitemid 46260272)
15. Brown J, Thorpe H, Napp V, et al. Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer. J Clin Oncol 2005;23:7417-7427. (Pubitemid 46291803)
16. Nicolaou N, Moughan J, Sarna L, et al. Quality of Life (QOL) Supercedes the Classic Predictors of Survival in Locally Advanced Non-Small Cell Lung Cancer (NSCLC): an analysis of Radiation Therapy Oncology Group (RTOG) 9801. Int J Radiat Oncol Biol Phys 2007;69:S58-S59.
17. Montazeri A, Gillis CR, McEwen J. Quality of life in patients with lung cancer: a review of literature from 1970 to 1995. Chest 1998;113:467-481.
18. Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 2008;26:1355-1363.
19. Sloan JA, Aaronson N, Cappelleri JC, Fairclough DL, Varricchio C; Clinical Significance Consensus Meeting Group. Assessing the clinical significance of single items relative to summated scores. Mayo Clin Proc 2002;77:479-487.
20. Montazeri A, Milroy R, Hole D, et al. Quality of life in lung cancer patients: as an important prognostic factor. Lung Cancer 2001;31:233-240. (Pubitemid 32107019)
21. Herndon JE II, Fleishman S, Kornblith AB, Kosty M, Green MR, Holland J. Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma? Cancer 1999;85:333-340. (Pubitemid 29051287)
22. Van Steen K, Curran D, Kramer J, et al. Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: identification and impact on model selection. Stat Med 2002;21:3865-3884. (Pubitemid 36032751)
23. Spitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis 1981;34:585-597. (Pubitemid 12237535)
24. Hollen PJ, Gralla RJ, Kris MG, Potanovich LM. Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer 1993;29A (Suppl 1):S51-S58.
25. Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995;12:199-220.
26. Johnson EA, Marks RS, Mandrekar SJ, et al. Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51). Lung Cancer 2008;60:200-207.
27. Temel JS, Pirl WF, Recklitis CJ, Cashavelly B, Lynch TJ. Feasibility and validity of a one-item fatigue screen in a thoracic oncology clinic. J Thorac Oncol 2006;1:454-459. (Pubitemid 47181423)
28. Butt Z, Wagner LI, Beaumont JL, et al. Use of a single-item screening tool to detect clinically significant fatigue, pain, distress, and anorexia in ambulatory cancer practice. J Pain Symptom Manage 2008;35:20-30.
29. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
30. BMI categorization. Center for Disease Control and Prevention. Available at: http://www.cdc.gov/nccdphp/dnpa/healthyweight/assessing/bmi/adult-BMI/about- adult-BMI.htm. Accessed on February 2, 2008.
31. Grambsch PM, Therneau TM, Fleming TR. Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. Biometrics 1995;51:1469-1482.
32. Grambsh PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515-526.
33. Jacot W, Colinet B, Bertrand D, et al; Oncolr Health Network. Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients. Ann Oncol 2008;19:1458-1464.
34. Gralla R, Hollen P, Eberley S. Quality of life score predicts both response and survival in patients receiving chemotherapy for non-small cell lung cancer [abstract]. Support Care Cancer 1995;3:378-379.
35. Eton DT, Fairclough DL, Cella D, Yount SE, Bonomi P, Johnson DH; Eastern Cooperative Oncology Group. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol 2003;21:1536-1543. (Pubitemid 46594107)
36. de Marinis F, Pereira JR, Fossella F, et al. Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer. J Thorac Oncol 2008;3:30-36.
37. Sloan JA, Dueck A. Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials. J Biopharm Stat 2004;14:73-96. (Pubitemid 38294753)
38. Sloan JA, Loprinzi CL, Kuross SA, et al. Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol 1998;16:3662-3673.
39. Huschka MM, Mandrekar SJ, Schaefer PL, Jett JR, Sloan JA. A pooled analysis of quality of life measures and adverse events data in north central cancer treatment group lung cancer clinical trials. Cancer 2007;109:787-795.
40. Smit EF, van Meerbeeck JP, Lianes P, et al; European Organization for Research and Treatment of Cancer Lung Cancer Group. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 2003;21:3909-3917.
41. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001;91:2214-2221. (Pubitemid 32552805)
42. Aoe K, Hiraki A, Ueoka H, et al. Thrombocytosis as a useful prognostic indicator in patients with lung cancer. Respiration 2004;71:170-173. (Pubitemid 38529173)
43. Colon-Otero G, Niedringhaus RD, Hillman SH, et al; North Central Cancer Treatment Group. A phase II trial of edatrexate, vinblastine, adriamycin, cisplastin, and filgrastim (EVAC/G-CSF) in patients with non-small-cell carcinoma of the lungs: a North Central Cancer Treatment Group Trial. Am J Clin Oncol 2001;24:551-555. (Pubitemid 33131413)
44. Marks RS, Graham DL, Sloan JA, et al. A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer. Am J Clin Oncol 2003;26:336-337. (Pubitemid 36962072)
45. Kanard A, Jatoi A, Castillo R, et al. Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a phase II trial of efficacy and toxicity. Lung Cancer 2004;43:345-353. (Pubitemid 38224156)
46. Jatoi A, Hillman S, Stella P, et al. Why do oncologists prescribe - or not prescribe - conventional chemotherapy to geriatric patients with metastatic non-small cell lung cancer? An exploratory study from the North Central Cancer Treatment Group. Submitted for publication.